# StableCoinX Inc.: financial statements, quarterly

USDE · Nasdaq · CIK 2080215 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/usde.md) · [Financials](/companies/usde/financials.md) · [Filings](/companies/usde/filings.md) · [Insiders](/companies/usde/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/usde/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: |
| Revenue | $m | [0.1](/filings/0001213900-26-090250.md) |
| Cost of revenue | $m | [0.0](/filings/0001213900-26-090250.md) |
| Research and development | $m | [0.0](/filings/0001213900-26-090250.md) |
| Selling, general and administrative | $m | [0.2](/filings/0001213900-26-090250.md) |
| Operating income | $m | [(36.4)](/filings/0001213900-26-090250.md) |
| Net income | $m | [(34.2)](/filings/0001213900-26-090250.md) |
| Diluted EPS | $ per share | [(15.27)](/filings/0001213900-26-090250.md) |
| Basic EPS | $ per share | [(15.27)](/filings/0001213900-26-090250.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2025-06-30) | period not labelled (2025-12-31) | period not labelled (2026-03-31) | period not labelled (2026-05-19) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Current assets | $m | not reported | [0.2](/filings/0001213900-26-090250.md) | not reported | not reported | [19.0](/filings/0001213900-26-090250.md) |
| Total assets | $m | not reported | [0.7](/filings/0001213900-26-090250.md) | not reported | not reported | [233](/filings/0001213900-26-090250.md) |
| Current liabilities | $m | not reported | [0.2](/filings/0001213900-26-090250.md) | not reported | not reported | [13.6](/filings/0001213900-26-090250.md) |
| Total liabilities | $m | not reported | [0.2](/filings/0001213900-26-090250.md) | not reported | not reported | [18.3](/filings/0001213900-26-090250.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | [0.0](/filings/0001213900-26-090250.md) | not reported |
| Shareholders' equity | $m | [0.8](/filings/0001213900-26-090250.md) | [0.5](/filings/0001213900-26-090250.md) | [0.1](/filings/0001213900-26-090250.md) | not reported | [214](/filings/0001213900-26-090250.md) |

- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Shares

| Line item | Unit | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: |
| Diluted shares (weighted) | thousands of shares | [2,238](/filings/0001213900-26-090250.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.